Treatment with acetylcholinesterase inhibitors for Alzheimer’s may reduce risk for AMD

Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.
“Given the possibility that AD medications could limit pathological inflammatory processes and protect against both oxidative stress and microvascular damage in the eye, we hypothesized that patients with AD treated with AChEIs may have a lower risk of incident AMD,” S. Scott Sutton, PharmD, from the Columbia VA Health Care System, and colleagues wrote.

Acetylcholinesterase inhibitors used to treat Alzheimer’s disease may also reduce the risk for developing age-related macular degeneration, according to a cohort study of older veterans published in JAMA Ophthalmology.
“Given the possibility that AD medications could limit pathological inflammatory processes and protect against both oxidative stress and microvascular damage in the eye, we hypothesized that patients with AD treated with AChEIs may have a lower risk of incident AMD,” S. Scott Sutton, PharmD, from the Columbia VA Health Care System, and colleagues wrote.